A Market Place Research – Page 2431

Prosthetic Heart Valve Market | LAMEA is expected grow at a high CAGR of 11.7% from 2017 to 2023

Prosthetic Heart Valve Market Expected to Reach $8,392 Million, Globally, by 2023

According to a new report published by Allied Market Research, titled, Prosthetic Heart Valve Market by Type: Global Opportunity Analysis and Industry Forecast, 2017-2023,” the global prosthetic heart valve market was valued at $3,874 million in 2016, and is expected to reach at $8,392 million by 2023, growing at a CAGR of 11.4% from 2017 to 2023. The transcatheter heart valve segment accounted for more than three-fifths share of the total market in 2016.

Download PDF Sample Report: https://www.alliedmarketresearch.com/request-sample/2176

The market is driven by rise in prevalence of cardiac disorders, such as rheumatic heart diseases, increase in geriatric population, and change in lifestyle of people, novel technological advancements in prosthetic heart valves, rise in patient awareness, demand for minimally invasive cardiovascular surgeries, and surge in transcatheter heart valve surgery centers. However, this growth is limited by high cost, risk associated with prosthetic heart valves, and stringent approval process for prosthetic heart valves. Use of transcatheter heart valves for new indications and emerging markets in Asia-Pacific and LAMEA are expected to provide several opportunities for key players operating in prosthetic heart valve market.

Key Findings of the Prosthetic Heart Valve Market

Based on product type, the transcatheter heart valve segment accounted for more than three-fifths of the total market in 2016.
Europe accounted for more than half of the transcatheter heart valve market (in terms of value) in 2016, with a CAGR of 13.8%.
Europe accounted for both, major share (nearly two-fifths) in 2016 (in terms of volume) and highest CAGR of 11.1% (for volume market) from 2017 to 2023, in the global market.
LAMEA is expected grow at a high CAGR of 11.7% from 2017 to 2023.

The major companies profiled in the report include Abbott Laboratories, Medtronic plc., Medical Technology Est., Boston Scientific Corporation; Micro Interventional Devices, Inc., Direct Flow medical, Inc., Edwards Lifesciences Corporation, LivaNova PLC., JenaValve Technology, Inc., and Cryolife, Inc.

Request Customization: https://www.alliedmarketresearch.com/request-for-customization/2176

Prosthetic Heart Valve Market Key Segments

By Product

Mechanical Heart Valve
Tissue Heart Valve
Stented Tissue Heart Valve
Stentless Tissue Heart Valve
Transcatheter Heart Valve

For Purchase Enquiry: https://www.alliedmarketresearch.com/purchase-enquiry/3020

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

Information Rights Management Market Demand, In-depth Analysis and Estimated Revenue Forecast Till 2026

Increase in trends of BOYD and increase in enterprise mobility in various organizations are the major factors that drive the market growth. In addition, increase in concern about information theft and loss as well as stringent regulations and compliance fuels the information rights management market growth.

However, high installation and integration cost and lack of awareness among people hamper the growth of the market. Furthermore, growing potential of IRM in developing nations and adoption of IRM by various SMEs is anticipated to create the major opportunities in the global market.

The information rights management market is segmented into component, deployment mode, organization size, industry vertical, and region. In terms of component, it is bifurcated into solution and services. The solution segment is further sub-divided into standalone solutions and integrated solutions.

The service segment is further sub-divided into professional service and managed services. Based on deployment mode, it is segmented into on-premise and cloud. As per organization size, the market is categorized into large enterprises and small & medium enterprises.

As per industry vertical, it is categorized into BFSI, retail & e-commerce, manufacturing, government & defense, energy & utilities, IT & telecom, education, healthcare, and others. Region-wise, the report includes information rights management market analysis across North America, Europe, Asia-Pacific, and LAMEA.

The information rights management market is dominated by key player such as Oracle Corporation, Microsoft Corporation, Seclore, Nextlabs Inc., Open Text Corporation, Vitrium, Micro Focus, Transperfect, Intralinks Inc., and Citrix Systems, Inc.

KEY BENEFITS FOR STAKEHOLDERS:

The study provides an in-depth analysis of the market along with the current information rights management market trends and future estimations to elucidate the imminent investment pockets.
Information about the key drivers, restraints, and opportunities and their impact analysis on the information rights management market share is provided.
Porter’s five forces analysis illustrates the potency of buyers and suppliers operating in the information rights management industry.
The quantitative analysis of the global information rights management market from 2019 to 2026 is provided to determine the market potential.

Thanks for reading this article; you can also get an individual chapter-wise section or region wise report versions like North America, Europe, or Asia.

If you have any special requirements, please let us know and we will offer you the report as per your requirements.

Lastly, this report provides market intelligence most comprehensively. The report structure has been kept such that it offers maximum business value. It provides critical insights into the market dynamics and will enable strategic decision-making for the existing market players as well as those willing to enter the market.

About Us:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP, based in Portland, Oregon. AMR provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients in making strategic business decisions and achieving sustainable growth in their respective market domains.

AMR launched its user-based online library of reports and company profiles, Avenue. An e-access library is accessible from any device, anywhere, and at any time for entrepreneurs, stakeholders, researchers, and students at universities. With reports on more than 60,000 niche markets with data comprising of 600,000 pages along with company profiles on more than 12,000 firms, Avenue offers access to the entire repository of information through subscriptions. A hassle-free solution to clients’ requirements is complemented with analyst support and customization requests.

Contact:
David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll-Free: 1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com
Follow Us on: LinkedIn Twitter

Immunoprecipitation Market Key Drivers, Restraints, And Opportunities Forecast, 2027

According to a new report published by Allied Market Research, titled, “Immunoprecipitation Market: Opportunity Analysis and Industry Forecast, 2020–2027,” The global immunoprecipitation market is expected to grow in the upcoming years. Increase in the research and development activities in the life science sector is boosting the growth of immunoprecipitation market. Immunoprecipitation is the procedure used for separation of specified protein from the solution. It uses antibody which can bind with the protein.

The Immunoprecipitation process is in rise due to increase in autoimmune disease cases which needs the antibody-antigen interaction for testing. Increased applications of immunoprecipitation processes in disorders such as cancer, cardiovascular diseases are boosting the growth of immunoprecipitation market.

𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐏𝐃𝐅 𝐁𝐨𝐮𝐜𝐡𝐞𝐫: https://www.alliedmarketresearch.com/request-sample/9869

COVID-19 Impact Analysis:

Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicines supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunity for manufacturers of COVID-19 management drugs, as many developed countries are short of these drugs. Owing to the demand for vaccine and treatment drugs for COVID-19, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future. Considering these factors, COVID-19 is expected to have significant impact on Immunoprecipitation Market.

𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞 𝐈𝐧𝐪𝐮𝐢𝐫𝐲: https://www.alliedmarketresearch.com/purchase-enquiry/9869

Advancements made in the immunoprecipitation techniques such as chromatin immunoprecipitation and chIP-seq have boosted immunoprecipitation market growth. Rise in funding from the government and non- government organizations for research and development purpose in next generation DNA sequencing and genomics is rising the growth of Immunoprecipitation market. Restrain factors such as limitations in sample size, differences seen in content of lipid can hamper the growth of immunoprecipitation market.

The key players profiled in this report include Thermo Fisher Scientific, Merck KGaA, GenScript Biotech Corporation, Bio-Rad Laboratories, Takara Bio Inc., Abbkine Scientific Co., Ltd, Cell Signaling Technology, Inc., Abcam plc.

𝐊𝐞𝐲 𝐁𝐞𝐧𝐞𝐟𝐢𝐭𝐬:

This study presents the analytical depiction of the Global Immunoprecipitation Market along with the current trends and future estimations to determine the investments.
The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the Immunoprecipitation Market share.
The current market is quantitatively analyzed from 2020 to 2027 to highlight the Immunoprecipitation Market growth scenario.
Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
The report provides a detailed Immunoprecipitation Market analysis based on competitive intensity and how the competition will take shape in coming years.

𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐂𝐮𝐬𝐭𝐨𝐦𝐢𝐳𝐚𝐭𝐢𝐨𝐧: https://www.alliedmarketresearch.com/request-for-customization/9869

𝐎𝐭𝐡𝐞𝐫 𝐓𝐫𝐞𝐧𝐝𝐢𝐧𝐠 𝐑𝐞𝐩𝐨𝐫𝐭𝐬:

North America and Europe Menstrual Cup Market: https://www.alliedmarketresearch.com/north-america-and-europe-menstrual-cup-market-A06126

Surgical Robotic System Market: https://www.alliedmarketresearch.com/surgical-robotic-systems-market-A06827

Surgical Drains Market: https://www.alliedmarketresearch.com/wound-drainage-surgical-drains-market-A07517

𝐀𝐛𝐨𝐮𝐭 𝐔𝐬:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP, based in Portland, Oregon. AMR provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

AMR introduces its online premium subscription-based library Avenue, designed specifically to offer cost-effective, one-stop solution for enterprises, investors, and universities. With Avenue, subscribers can avail an entire repository of reports on more than 2,000 niche industries and more than 12,000 company profiles. Moreover, users can get an online access to quantitative and qualitative data in PDF and Excel formats along with analyst support, customization, and updated versions of reports.

Contact:

David Correa
5933 NE Win Sivers Drive
205, Portland, OR 97220
United States
Toll Free: 1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com

Pneumonia Testing Market | China is expected to grow highest in the Asia-Pacific region during the forecast period

Pneumonia Testing Market Expected to Reach $1,738 Million, Globally, by 2023

According to a new report published by Allied Market Research, titled, Pneumonia Testing Market by Method, Technology, Type, End User, and Geography: Global Opportunity Analysis and Industry Forecast, 2017-2023, the pneumonia testing market accounted for $932 million in 2016, and is estimated to reach $1,738 million by 2023, registering a CAGR of 9.2% from 2017 to 2023.. North America is the highest contributor in the pneumonia testing market in 2016; however, Asia-Pacific is expected to witness the highest growth rate during the forecast period.

Download PDF Sample Report: https://www.alliedmarketresearch.com/request-sample/3776

The global pneumonia testing market is segmented on the basis of market, by method, type, technology, end user, and region. In terms of method, the market is classified into immunodiagnostics, molecular diagnostics, and point-of-care (POC) testing. By type, it is bifurcated into analyzers and consumables. Based on technology, it is categorized into enzyme linked immunosorbent assay (ELISA), immunofluorescence, western blot, polymerase chain reaction (PCR), immunohistochemistry (IHC), and others. Depending on end user, it is divided into hospitals, diagnostic laboratories, homecare, and others. Based on region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings of the Pneumonia Testing Market:

POC testing is projected to grow at the highest rate during the analysis period.
Diagnostic laboratories segment generated the highest revenue, and is expected to continue its dominance in future.
North America dominated global pneumonia testing market in 2016, and is projected to continue its dominance in future.
China is expected to grow highest in the Asia-Pacific region during the forecast period.
ELISA was the largest contributor among the technologies segments.

The key companies profiled in the report include Thermo Fisher Scientific Inc., Abbott Laboratories, F-Hoffmann la Roche Ltd., Hologic Inc., bioMerieux, Becton, Dickenson and Company, Bio-Rad Laboratories Inc., Meridian Biosciences, Quest Diagnostics, and Quidel.

Request Customization: https://www.alliedmarketresearch.com/request-for-customization/3776

Key Market Segments

By Type
Analyzers
Consumables

By End User
Hospitals
Diagnostic Laboratories
Homecare
Others

By Method
Immunodiagnostics
Molecular Diagnostics
Point of Care (POC) Testing

By Technology
Enzyme-linked Immunosorbent Assay (ELISA)
Immunofluorescence
Western Blot
Polymerase Chain Reaction (PCR)
Immunohistochemistry (IHC)

Recent advancement in pneumonia testing systems such as the development of enhanced nucleic acid detection tests and advancement in POC tests is the major factor that contributes toward the growth of the pneumonia testing market. Moreover, increase in awareness toward early diagnosis and rise in government expenditures on healthcare fuel the market growth. However, limited detection capability & accuracy of some of the pneumonia testing products and regulatory & economic hurdles hamper the market growth. Conversely, surge in adoption of molecular diagnostic testing and high untapped market potential in the developing economies are anticipated to provide lucrative opportunities for the market.

For Purchase Enquiry: https://www.alliedmarketresearch.com/purchase-enquiry/3776

Similar Reports:

Microcatheters Market

Slide Stainer Market

About Us

Ulcerative Colitis Market 2022 | The injectable segment is expected to register the highest CAGR of 6.9%.

Ulcerative Colitis Market Expected to Reach $4,785 Million by 2023

According to a new report published by Allied Market Research, titled, Ulcerative Colitis Market by Disease Type, Route of Administration, and Molecule Type: Global Opportunity Analysis and Industry Forecast, 2017-2023, the global ulcerative colitis market was valued at $4,785 million in 2016, and is expected to reach $7,455 million by 2023, registering a CAGR of 6.5% from 2017 to 2023. The mild ulcerative colitis disease type accounted for nearly half of the market share in 2016.

The prime factors factor that drive global ulcerative colitis market are increase in prevalence of ulcerative colitis globally and rise in R&D activities by key players towards new drug formulations for disease treatment. In addition, increase in patient assistance programs that has raised the demand for branded drugs further fuels the market growth. Untapped emerging economies that lack proper medical assistance are expected to provide numerous opportunities for market expansion.

Download PDF Sample Report: https://www.alliedmarketresearch.com/request-sample/3965

The key players operating in the global ulcerative colitis market are Johnson & Johnson, GlaxoSmithKline plc, Eli Lilly and Co., Sanofi Aventis A/S, AstraZeneca plc, Merck & Co., Inc., InDex Pharmaceuticals Holding AB, Ajinomoto Pharmaceuticals Co., Ltd., and Abbott Laboratories. The other prominent players in the value chain include Avaxia Biologics Inc., BioLineRx Ltd., Celgene Corporation, Mitsubishi Tanabe Pharma Corporation, and Salix Pharmaceuticals, Inc.

Key Market Players

PFIZER INC.
JOHNSON & JOHNSON
GLAXOSMITHKLINE PLC
ELI LILLY AND CO.
SANOFI AVENTIS A/S
ASTRAZENECA PLC
MERCK & CO. INC.
ABBOTT LABORATORIES
INDEX PHARMACEUTICALS HOLDING AB
AJINOMOTO PHARMACEUTICALS CO., LTD.

Key Findings of the Ulcerative Colitis Market:

The severe disease type segment is anticipated to grow with a CAGR of 6.7% from 2017 to 2023.
U.S. was the highest shareholder in the North American ulcerative colitis market in 2016, and is poised to retain its lead during the forecast period.
Biologics registered the highest CAGR of 6.9%.
India is expected to grow at a significant rate of 7.1%.
The small molecules segment accounted for half of the share in 2016, registering a CAGR of 6.1%.

Request Customization: https://www.alliedmarketresearch.com/request-for-customization/3965

Key Market Segments

By Route Of Administration
Oral
Injectables

By Disease Type
Mild Ulcerative Colitis
Moderate Ulcerative Colitis
Severe Ulcerative Colitis

By Molecule Type
SMALL MOLECULES
BIOLOGICS

For Purchase Enquiry: https://www.alliedmarketresearch.com/purchase-enquiry/3965

About Us

Intravascular Temperature Management Market gained substantial share in recent years due to rise in surgical procedures

Intravascular Temperature Management Market Expected to Reach $335,192 Thousand by 2025

The factors that drive the growth of the intravascular temperature management market include rise in number of surgical procedures performed across globe and surge in adoption of intravascular temperature management across the globe.

According to a new report published by Allied Market Research, titled, Intravascular Temperature Management Market, by Product, Application, Indication, and End User: Global Opportunity Analysis and Industry Forecast, 2018-2025,” the market was valued at $261,556 thousand in 2017, and is projected to reach $335,192 thousand in 2025, registering a CAGR of 3.1% from 2018 to 2025.

Download PDF Sample Report: https://www.alliedmarketresearch.com/request-sample/5045

Intravascular temperature management is a technique applied to reach and maintain proper temperature in a patients body in operation theaters, recovery rooms, and intensive care units. Intravascular temperature management is used to cool or warm the blood to maintain the body temperature, which facilitates health improvement and reduces the risk of surgical site infections. The technique is also used in patients with hyperthermia or hypothermia. The procedure involves a system that is used to infuse cold or hot saline in a patients body with the help of a closed network catheter.

Key findings of the Intravascular Temperature Management Market:

The consumables segment accounted for more than two-thirds share of the global intravascular temperature management market in 2017.
The preoperative care segment is expected to grow at the highest CAGR from 2017 to 2025.
The non-sterile intravascular temperature management segment accounted for around one-fourth share of the global intravascular temperature management market in 2017.
Europe accounted for around one-fourth share of the global market in 2017.
LAMEA is expected to provide lucrative growth opportunities from 2017 to 2025.

North America was the leading revenue contributor to the global intravascular temperature management market in 2017 and is expected to maintain its dominance during the forecast period. This is attributed to high purchasing power and easy availability of devices in this region. However, Asia-Pacific is expected to grow at the highest CAGR during the forecast period, owing to increase in affordability and rise in healthcare expenditure.

Key Market Segments

BY PRODUCT
System
Consumables

BY END USER
Surgical Centers
Emergency Care Units
Ambulatory Surgical Centers

BY APPLICATION
Preoperative Care
Operative Care
Post-operative Care
Acute/Critical Care

Request Customization: https://www.alliedmarketresearch.com/request-for-customization/5045

Key Market Players

3M Company
Asahi Kasei Corporation. (ZOLL Medical Corporation.)
Belmont Instrument Corporation
Biegler GmbH
Geratherm Medical AG
Smiths Group Plc
Stryker Corporation
Stihler Electronic GmbH
The Surgical Company BV
VYAIRE ME
DICAL INC

For Purchase Enquiry:https://www.alliedmarketresearch.com/purchase-enquiry/5045

About Us

Antihyperlipidemic Drugs Market | Asia-Pacific region would exhibit the highest CAGR of 8.6% during 2019-2026

Global Antihyperlipidemic Drugs Market Expected to Reach $16 Billion by 2026

Asia-Pacific is estimated to register the fastest growth during the forecast period, owing to surge in awareness related to the use of antihyperlipidemic drugs.According to a new report published by Allied Market Research, titled, “Antihyperlipidemic Drugs Market by Drug Class: Global Opportunity Analysis and Industry Forecast, 2019–2026,” the global antihyperlipidemic drugs market was valued at $9,456 million in 2018, and is expected to reach $16,865 million by 2026, registering a CAGR of 7.5% from 2019 to 2026.

The rise in level of lipids in the blood is called as hyperlipidemia. The drugs that are used to treat the condition are called antihyperlipidemic drugs. Furthermore, there are major complications associated with this condition such as heart attack. Therefore, the condition requires early monitoring and treatment. Some of the antihyperlipidemic drugs available in the market include statins, bile acid sequestrants, cholesterol, and others.

Download PDF Sample Report: https://www.alliedmarketresearch.com/request-sample/6284

The antihyperlipidemic drugs market size is studied based on segments, drug class, and region to provide a detailed assessment of the market. Based on drug class, the market is divided into statins, PCSK9 inhibitors, bile acid sequestrants, cholesterol absorption inhibitors, fibric acid derivatives, and combination. Based on region, it is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, and rest of LAMEA).

Key Market Segments

By Drug Class
Statins
Bile Acid Sequestrants
Cholesterol Absorption Inhibitors
Fibric Acid Derivatives
PCSK9 Inhibitors
Combination
Others

Key Findings of the Study:

Statins occupied one-third share of the global antihyperlipidemic drugs market in 2018.
The PCSK9 inhibitors segment is anticipated to grow with the highest CAGR throughout the forecast period.
The cholesterol absorption inhibitors segment accounted for more than one-fourth share of the market in 2018.
Asia-Pacific is anticipated to grow at the highest rate during the analysis period, followed by LAMEA.

Request Customization: https://www.alliedmarketresearch.com/request-for-customization/6284

Key Market Players

ABBVIE INC.
Amgen Inc.
AstraZeneca plc
Bristol-Myers Squibb Company
Daiichi Sankyo Company, Limited
Dr. Reddy’s Laboratories Ltd
Merck & Co., Inc
Mylan N.V
Pfizer Inc.
SANOFI S.A

In 2018, North America accounted for the major share of antihyperlipidemic drugs market size, and is expected to remain dominant during the forecast period, owing to easy availability of the antihyperlipidemic drugs. Moreover, surge in the sedentary lifestyle is another major factor that contributes to the growth of the market. Furthermore, surge in the obese population is another major factor that fuels the growth of the antihyperlipidemic drugs market. In addition, the presence of major key players such as Abbvie Inc., Amgen Inc., Bristol-Myers Squibb Company, Merck & Co., Inc. and others is another major factor that fuels the growth of antihyperlipidemic drugs market in the region.

For Purchase Enquiry: https://www.alliedmarketresearch.com/purchase-enquiry/6284

About Us

Digestive Enzymes Market: Animal Origin Segment Registered Highest Market Share

According to a new report published by Allied Market Research, titled, “Digestive Enzymes Market: Opportunity Analysis and Industry Forecast, 2020–2027,” Digestive enzymes consists of group of enzymes that breakdown complex macromolecules into their constituents and also aid in catalysis of chemical reactions, in order to facilitate their absorption by the body. These proteins are secreted by digestive organs like pancreas, gallbladder and liver. Digestive enzymes are used to enhance nutritional value to the diet and to lower the risks of wide range of health problems including indigestion, irritable bowel syndrome, constipation, chronic pancreatitis, muscle mass gaining and obesity. Change in acidic to alkaline conditions in the gastrointestinal tract, affect the efficacy of digestive enzymes. Hence, to facilitate enzyme effectiveness, digestive enzyme supplements are accessible in the market in various formulations to adapt to the change in pH conditions. The availability of digestive enzymes is in several forms like pills, capsules, powders or liquids, and are of various types including Amylase, Lactase, Lipase, Maltase, Protease and Sucrase. Supplementation of enzymes play an anchoring role in management of digestive disorders, from cystic fibrosis to lactose intolerance.

𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐏𝐃𝐅 𝐁𝐨𝐮𝐜𝐡𝐞𝐫: https://www.alliedmarketresearch.com/request-sample/8563

COVID-19 Impact Analysis:

The COVID-19 pandemic has emerged as a humanitarian as well as economic crisis, creating strain on the society and affecting millions of people and businesses
Industry closures and people are asked to stay in their homes which has cause taken a huge toll in terms of money and economic growth
Over 4 million people affected globally, with 300 thousand losing their lives due to novel coronavirus
Healthcare organizations are already working in battle mode, preparing new plans to respond growing COVID-19 patients, right from sourcing rapid diagnosing kits to sufficient PPE kits for workers
Due to diversion of medical field towards treating COVID-19, the funding to R&D activities related to chondroitin sulfate has been reduced and this segment have to face negligence subsequently causing negative impact on digestive enzymes market.

𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞 𝐈𝐧𝐪𝐮𝐢𝐫𝐲: https://www.alliedmarketresearch.com/purchase-enquiry/8563

Numerous factors such as sedentary lifestyles, desk-bound jobs with hectic work schedules, high consumption of fast food along with packaged food often results in digestive problems. Growing demand for these products in the wake of fitness conscious population is anticipated aid in market expansion over coming years. In addition, surging number of fitness centers and gymnasiums has also increased the demand for dietary supplements and the rising awareness regarding nutraceuticals and its benefits, increasing awareness about GI health, and focus on preventive disease management is also contributing in the growth of digestive enzymes market. Digestive enzymes owing to their various advantages, aid in the treatment of pancreatic disorders and gastrointestinal diseases. Moreover, rising awareness towards pancreatic surgeries, easy accessibility to over-the-counter drugs will likely augment market growth over the upcoming years.

The key players profiled in this report include Allergan PLC, Abbvie Inc., Amway Corporation, Country Life LLC., National Enzyme Company, Garden Of Life Inc., Biotics Research Corporation, Matsun Nutrition, Metagenics, Inc., and Abbott Nutrition.

𝐊𝐞𝐲 𝐁𝐞𝐧𝐞𝐟𝐢𝐭𝐬:

This study presents the analytical depiction of the global digestive enzymes industry along with the current trends and future estimations to determine the imminent investment pockets.
The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global digestive enzymes market share.
The current market is quantitatively analyzed from 2020 to 2027 to highlight the global digestive enzymes market growth scenario.
Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
The report provides a detailed global digestive enzymes market analysis based on competitive intensity and how the competition will take shape in coming years.

𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐂𝐮𝐬𝐭𝐨𝐦𝐢𝐳𝐚𝐭𝐢𝐨𝐧: https://www.alliedmarketresearch.com/request-for-customization/8563

𝐎𝐭𝐡𝐞𝐫 𝐓𝐫𝐞𝐧𝐝𝐢𝐧𝐠 𝐑𝐞𝐩𝐨𝐫𝐭𝐬:

North America and Europe Menstrual Cup Market: https://www.alliedmarketresearch.com/north-america-and-europe-menstrual-cup-market-A06126

Surgical Robotic System Market: https://www.alliedmarketresearch.com/surgical-robotic-systems-market-A06827

Surgical Drains Market: https://www.alliedmarketresearch.com/wound-drainage-surgical-drains-market-A07517

𝐀𝐛𝐨𝐮𝐭 𝐔𝐬:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP, based in Portland, Oregon. AMR provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

Contact:

Irritable bowel syndrome market growth 2022 attributed to rise in prevalence of gastrointestinal disease the globe

Irritable Bowel Syndrome Treatment Market Expected to Reach $2,012 Million by 2026

The major factors that boost the growth of the global irritable bowel syndrome treatment market are adoption of sedentary lifestyle, rise in level of stress, unhealthy diet, rise in geriatric population, surge in prevalence of gastrointestinal diseases and disorders such as alteration of bowel habit, & abdominal pain, increase in awareness programs for irritable bowel syndrome treatment, and launches of various developed pipeline drugs for the irritable bowel syndrome treatment during the forecast period.

Download Sample Report : https://www.alliedmarketresearch.com/request-sample/6313

According to a new report published by Allied Market Research, titled, “Irritable Bowel Syndrome Treatment Market by Type, Product, and End User: Global Opportunity Analysis and Industry Forecast, 2019–2026,” the global irritable bowel syndrome treatment market size was valued at $ 1,071 million in 2018, and is projected to reach $2,012 million by 2026, growing at a CAGR of 8.2% from 2019 to 2026.

By product, the rifaximin segment accounted for the highest revenue share in the irritable bowel syndrome treatment market in 2018, and is expected to maintain its dominance during the forecast period. This is attributed to adoption of sedentary lifestyle and rise in geriatric population. In addition, launches of various developed pipeline drugs for the irritable bowel syndrome treatment and rise in awareness programs are expected to offer remunerative opportunities for market expansion in the near future.

Key Market Players

Abbott Laboratories
Allergan plc
Ardelyx Inc.
Astellas Pharma Inc.
AstraZeneca plc
GlaxoSmithKline Plc
Johnson & Johnson (McNeil Consumer Healthcare)
Novartis AG
Sebela Pharmaceuticals Inc.
Takeda Pharmaceutical Company Ltd.

Key Findings of the Study:

Based on type, the IBS with diarrhea (IBS-D) segment held 47.76% share in the global market in 2018.
Based on product, the rifaximin segment accounted for the largest irritable bowel syndrome treatment market share in 2018 and is expected to remain dominant throughout the forecast period.
Based on end user, the drug stores & retail pharmacies segment held 54.01% share in the global market in 2018.
Based on region, Asia-Pacific is expected to experience growth at the highest rate, registering a CAGR of 9.9% during the forecast period.
North America accounted for the major share in the irritable bowel syndrome market size and is expected to continue this trend, owing to availability of well-developed infrastructure facilities, presence of majority of the key players, rise in gastrointestinal diseases, and huge availability of trained medical professionals. On the other hand, Asia-Pacific is estimated to register the fastest growth during the forecast period, owing to rise in disposable income, high population base, surge in the geriatric population, and increase in patient awareness toward irritable bowel syndrome treatment.

Request Customization: https://www.alliedmarketresearch.com/request-for-customization/3020

Key Market Segments

By Type
IBS with Diarrhea (IBS-D)
IBS with Constipation (IBS-C)
Mixed-presentation IBS (IBS-M)

By Product
Rifaximin
Eluxadoline
Lubiprostone
Linaclotide
Others

By End User
Hospitals Pharmacies
Drug Stores & Retail Pharmacies
Online Pharmacies

For Purchase Enquiry: https://www.alliedmarketresearch.com/purchase-enquiry/6313

About Us

Uveitis Treatment Market | Asia-Pacific region would exhibit the highest CAGR of 6.0% during 2019-2026

Global Uveitis Treatment Market Expected to Reach $687 Million by 2026

Asia-Pacific presents lucrative opportunities for the key players operating in the uveitis treatment market, owing to growth in awareness regarding uveitis treatment and rise in adoption of uveitis treatment products.According to a new report published by Allied Market Research, titled, ” Uveitis Treatment Market by Drug Class, Disease Type, and Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2019–2026,” the global uveitis treatment market size was valued at $478 million in 2018, and is projected to reach $687 million by 2026, growing at a CAGR of 4.6% from 2019 to 2026.

Download Sample Report at https://www.alliedmarketresearch.com/request-sample/6359

The uveitis treatment market is expected to experience significant growth during the forecast period, owing to rise in demand for uveitis treatment medication across geographies with increase in popularity advanced therapeutics. Furthermore, increase in prevalence of uveitis with early detection further boost the uveitis treatment market growth during the forecast period. However, lack of adverse effects associated with the use of drugs may hamper the market growth. Moreover, significant unmet need for uveitis treatment and innovative molecules in pipeline further create lucrative opportunities for uveitis treatment market.

Based on drug class, the uveitis market is categorized into anti-inflammatory, antimicrobial drugs, immunotherapy & targeted therapies, and others. Currently, anti-inflammatory is major revenue contributing segment and is estimated to witness significant market growth during the forecast period due to adoption of anti-inflammatory as first line treatment of uveitis. On the other hand, immunotherapy & targeted therapies segment is expected to witness fastest market growth due to rise in demand for ideal therapeutics for treatment of uveitis. Targeted therapies include biologic drugs that target certain parts of immune system to stop inflammation. Drugs such as abatacept, adalimumab, daclizumab, infliximab, rituximab, and others are used to treat severe uveitis.

Key Findings of the Study:

Based on drug class, the anti-inflammatory segment held approximately half of the share in the global market in 2018.
Based on distribution channel, the online pharmacies segment exhibits fastest growth and is expected to grow at a CAGR of 5.9% from 2019 to 2026.
Based on application, the anterior uveitis segment held largest market share in 2018 and is expected to remain dominant throughout the forecast period.
Based on region, Asia-Pacific is expected to experience growth at the highest rate, registering a CAGR of 6.0% during the forecast period.
North America accounted for approximately one-half of the global uveitis treatment market share in 2018 and is expected to remain dominant throughout the forecast period. This was attributed to the higher adoption of ideal uveitis treatment medication, higher number of R&D activities to develop ideal therapeutics, large number of target population with higher health awareness, availability of trained medical professionals, and supportive reimbursement policies in the healthcare system. Asia-Pacific is expected to experience the highest growth rate during the forecast period majorly due to growth in prevalence of uveitis with increase in adoption of uveitis treatment medication.

Key Market Players

AbbVie Inc.
Alimera Sciences, Inc.
Allergan Plc.
Amgen Inc.
Bausch Health Companies Inc. (Bausch & Lomb Incorporated)
Clearside Biomedical, Inc.
EyePoint Pharmaceuticals, Inc.
Mylan N.V.
Novartis AG
Santen Pharmaceutical Co., Ltd.

Request Customization : https://www.alliedmarketresearch.com/request-for-customization/6359

Key Market Segments

By Disease Type
Anterior Uveitis
Posterior Uveitis
Intermediate Uveitis
Panuveitis

By Distribution Channel
Hospital Pharmacies
Drug Stores & Retail Pharmacies
Online pharmacies

For Purchase Enquiry: https://www.alliedmarketresearch.com/purchase-enquiry/6359

About Us